shengnuo biotechnology company was surveyed by 10 institutions: The company’s technological research and development strength in the field of peptide drugs also ensures the successful launch of the company’s own preparations, and it has an integrated industrial chain and cost advantages of raw materials and preparations (with survey questions and answers)

shengnuo biotechnology company released an investor relations activity record form on September 25. The company was surveyed by 10 institutions on September 21, 2023. The types of institutions are QFII, insurance companies, others, fund companies, overseas institutions, and securities companies.

Introduction to the main contents of investor relations activities: 1. Company introduction Chengdu Sennuo Biotechnology Co., Ltd. was established in July 2001 and is a high-tech certified enterprise in Sichuan Province. At the beginning of its establishment, the company mainly provided CDMO services such as small trials, pilot trials, process research and development, and customized peptide production of peptide drugs for domestic peptide pharmaceutical companies and R&D institutions.

In the process, it established a GMP-grade API and preparation production line. With a full-process R&D pipeline and a full-industry chain platform, it has accumulated a high reputation in the field of domestic peptide drugs. It has provided pharmaceutical research services for more than 40 projects for a number of new drug R&D companies and scientific research institutions, of which 1 variety has been approved for marketing.

Entering the commercialization stage, 19 innovative peptide drugs have entered the clinical trial stage. The company continues to accumulate experience in the process of drug R&D and production, and independently selects peptide generic drugs with large market space and development prospects at home and abroad for R&D, becoming one of the most powerful peptide R&D and production companies in the country. 2. Interactive communication

Question: The company’s net profit increased in the first half of the year, but why did the net profit attributable to shareholders of the listed company, excluding non-recurring gains and losses, decline?

Answer: The net profit attributable to shareholders of listed companies after deducting non-recurring gains and losses in the first half of the year was 9.2579 million yuan, a year-on-year decrease of 38.18%.

This was mainly due to the increase in new loans of 150 million yuan this year, which led to an increase in financial expenses compared with the same period last year, followed by administrative expenses. Due to the increase and the payment of processing fees for waste organic solvents, packaging barrels, etc. that cannot be recycled and environmental consulting service fees.

Question: How does the company view the current off-label use of semaglutide for weight loss?

Answer: Currently, Novo Nordisk’s semaglutide product has been approved for weight loss and hypoglycemic indications in the U.S. market. The product has been approved for hypoglycemic indications in China. According to the drug clinical trial registration and Information disclosure platform, in August last year, Novo Nordisk Smeglutide Injection “Adjuvant treatment with a low-calorie diet and increased physical activity is used for initial body mass index (BMI) ≥30kg/m2 (obesity), or ≥27kg/m2″ m2 and <30kg/m2 (overweight) and accompanied by at least one overweight-related comorbidity” Phase III clinical trial for the indication has been completed. Many domestic companies are also deploying semaglutide injection. However, this product is currently still under patent protection. The company’s semaglutide API and injection projects are currently in the pharmaceutical research stage.

Question: Where is the synergy between the company’s various businesses?

Answer: The company started in the peptide CDMO business. After years of intensive cultivation, it has accumulated enough customer resources in the industry and enjoys an excellent reputation through past successful cases. After the CDMO order is completed, once the customer’s preparation is on the market, due to the deep binding of the previous business, it is very likely to continue to purchase the API provided by the company, transforming the company’s role from a service provider to a supplier, thus forming a diversion to API customers. , forming business linkage from CDMO to APIs. The company’s technological research and development strength in the field of peptide drugs also ensures the successful launch of the company’s own preparations, and it has an integrated industrial chain and cost advantage of raw materials and preparations.

Question: What is the reason for the booming development of the peptide drug market in recent years?

Answer: Among the new drugs newly approved by the FDA in recent years, peptide drugs account for a higher proportion. The success rate of researching innovative peptide drugs is higher than that of small molecules, and peptide drugs have fewer side effects. In addition, in recent years, technological innovations in the industry have continued to emerge. Reducing the frequency of dosing and the emergence of oral preparations have improved patients’ acceptance of peptide drugs; at the same time, in terms of indications, it is not only in the traditional fields of diabetes and cancer. , peptide drugs have shown good application prospects in the fields of weight loss, non-alcoholic steatohepatitis (NASH), Alzheimer’s and other fields.

Question: What APIs does the company currently have? How does the company consider when selecting APIs for R&D?

Answer: The company’s existing API products: enfuvirtide, bivalirudin, eptifibatide, icatibant, liraglutide, atosiban acetate, carbetocin, octreotide acetate, growth Instatin, thymosin, etc., and there are many varieties under research. The company continues to accumulate experience in the drug research and development and production process, and independently selects peptide generic drugs with large market space and development prospects at home and abroad for research and development.

Question: What are the advantages of the company’s long-chain peptide coupling technology, PEGylation modification of side chain groups, and fatty acid modification technology?

Answer: As the peptide sequence lengthens, the efficiency of the peptide coupling reaction becomes lower and lower, and due to the spatial structure or specific sequence of some sites, conventional peptide coupling methods are used at some sites or intervals. The coupling efficiency is very low, resulting in a serious decline in product quality and yield;

our company’s long-chain peptide coupling uses specific coupling conditions to solve problems such as low coupling efficiency and amino acid racemization that are prone to occur in the long peptide coupling process. , ensuring high coupling efficiency of each amino acid, thereby obtaining high overall product yield and quality. This technology realizes large-scale automated production of long-chain polypeptide drugs, while fragment condensation or genetic engineering technology is commonly used abroad. Natural peptide sequences are easily degraded in the body, so the half-life is short. It is very inconvenient for patients with chronic diseases to take the medicine 1-2 times a day.

For example, the half-life of exenatide is extended by more than 50 times after being modified with PEGylation modification technology. The frequency is reduced to once a week, which greatly facilitates patients’ medication use.

Question: What impact does carbetocin have on the company through consistency evaluation?

Answer: Carbetocin injection has passed the quality and efficacy consistency evaluation of generic injection drugs, which is a reflection of the company’s comprehensive strength in R&D, production and quality management systems, and has accumulated rich experience for the company’s subsequent consistency evaluation product research; at the same time It will help improve the market competitiveness of the product and have a positive impact on the company’s future operating performance;